SCHEMBL27162495

SCHEMBL27162495

CC(C)(C)CCN1CCC2(CCCN(S(=O)(=O)c3ccc(N4CCC5(CCCO5)CC4)nc3)C2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.41
▸ ALDH1A1 P00352 7/20 0.40
▸ HSD17B10 Q99714 5/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ LMNA P02545 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TSHR P16473 5/20 0.38
▸ CYP3A4 P08684 6/20 0.38
▸ CYP1A2 P05177 5/20 0.38
▸ CYP2D6 P10635 4/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ USP2 O75604 3/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ KCNJ1 P48048 1/20 0.37
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30049747 1.00 GAA (0.44) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL30049856 0.97 GAA (0.43) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL27162782 0.97 GAA (0.43) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL30049987 0.92 GAA (0.43) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL27161879 0.92 GAA (0.43) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL27162056 0.92 GAA (0.46) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL30049944 0.92 GAA (0.46) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL30049877 0.89 ALDH1A1 (0.53) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL27162435 0.89 ALDH1A1 (0.53) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10
SCHEMBL30050954 0.88 GAA (0.44) GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 GAA 3700/4885KDM4E 3959/4885SMN1; SMN2 3118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback